Can LY2140023 reduce schizophrenia symptoms?
During the four-week study, patients either took two daily pills containing LY2140023, a daily shot of the antipsychotic drug olanzapine, or a pill containing no medicine ( placebo ). Patients taking LY2140023 or olanzapine had a reduction in their schizophrenia symptoms, compared to patients taking the placebo.
What is the status of the Eli Lilly LY2140023 trial?
Eli Lilly is planning to launch a multi-centre, double-blind and placebo-controlled Phase III study on LY2140023 in March 2011. The trial will enrol 950 patients and is expected to be concluded by February 2013. The study will determine efficacy of at least one dose level of LY2140023 compared to placebo.
What are the side effects of Lilly’s new schizophrenia drug?
But schizophrenia researchers said the trial’s results were surprising and impressive, especially since the drug works in a different way from existing antipsychotic medicines, all of which have serious side effects, including substantial weight gain and tremors. Lilly will begin a larger clinical trial for the drug this month.
What is the difference between LY2140023 and other antipsychotic drugs?
Lilly’s LY2140023 differs from established antipsychotic drugs in that it targets glutamate rather than dopamine or serotonin receptors. There is a substantial body of evidence to suggest that glutamate, a neurotransmitter, may also be involved in the pathophysiology of schizophrenia.
How much did schizophrenia drugs cost in 1993?
Figure 1: Worldwide sales of drugs for schizophrenia, 1993–2007. The schizophrenia drug market has grown from less than $1 billion annually in 1993 to more than $10 billion. This rapid growth has followed the introduction of Risperdal in 1993, followed by Zyprexa, Seroquel, Geodon (ziprasidone; Pfizer) and Abilify (aripiprazole;
Does Eli Lilly have a ly2140023?
In September 2007, Eli Lilly announced results of a 4-week Phase II trial of their metabotropic glutamate receptor 2/3 (mGluR2/3) agonist LY2140023 for schizophrenia. Although LY2140023 exhibited slightly less efficacy than Zyprexa in reducing positive symptoms, it nonetheless delivered significant improvement 2. Importantly, while treatment with Zyprexa was associated with weight gain, patients who received LY2140023 actually lost an average of 0.5 kg. These data indicate that mGluR agonists could represent a breakthrough in the search for a better-tolerated antipsychotic.
Does ly2140023 cause weight gain?
Importantly, while treatment with Zyprexa was associated with weight gain, patients who received LY2140023 actually lost an average of 0.5 kg. These data indicate that mGluR agonists could represent a breakthrough in the search for a better-tolerated antipsychotic.
Is zyprexa the most effective antipsychotic?
Zyprexa is widely regarded as being the most effective atypical antipsychotic on the market, but in the past 3 years, issues related to side effects have led to the drug losing nearly half its market share, as well as over 28,000 lawsuits, again indicating the need for drugs with better side-effect profiles.
Does mGluR2/3 inhibit dopamine release?
In addition, mGluR2 /3 agonists have been shown to inhibit dopamine release, demonstrating functional interconnectivity of these two neurotransmitter pathways. It remains possible that mGluR2/3 agonists may in fact target the conventional pathway of dopamine D 2 antagonism.